Glucagon-like peptide 1 receptor agonists in obesity treatment - a literature review

Glucagon-like peptide 1 receptor agonists in obesity treatment - a literature review

Introduction and Purpose: Obesity is an escalating global health challenge, affecting over 2 billion individuals worldwide, contributing to many challenges for healthcare providers such as cardiovascular disorders, cancers, and type 2 diabetes mellitus. There is a need for effective treatments targe...

Full description

Saved in:

Bibliographic Details
Main Authors:	Aleksander Jentkiewicz, Esmail Haj Obeid, Jakub Ulrych, Jan Krupa, Maciej Malinowski, Michał Krasowski, Alicja Kalinowska, Wiktoria Pietras, Adrian Kozieł, Zofia Kurek
Format:	Article
Language:	English
Published:	Kazimierz Wielki University 2025-02-01
Series:	Journal of Education, Health and Sport
Subjects:	tirzepatide semaglutide weight loss GLP-1 receptor agonists obesity treatment liraglutide
Online Access:	https://apcz.umk.pl/JEHS/article/view/57712
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Physician Perceptions of the Safety and Efficacy of GLP-1 Receptor Agonists: Underestimation of Cardiovascular Risk Reduction and Discrepancies with Clinical Evidence
by: Srikanth Krishnan, et al.
Published: (2025-01-01)

The role of glucagon-like peptide-1 receptor (GLP-1R) agonists in enhancing endothelial function: a potential avenue for improving heart failure with preserved ejection fraction (HFpEF)
by: Darshan Hullon, et al.
Published: (2025-02-01)

Glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide agonists for the treatment of obesity and diabetes mellitus
by: Alexander C. Martins, et al.
Published: (2024-04-01)

Comparison of GLP-1RAs vs Other Pharmacotherapy for Obesity
by: Andrew Overholser, et al.
Published: (2025-02-01)

GLP‐1 Receptor Agonists Alleviate Diabetic Kidney Injury via β‐Klotho‐Mediated Ferroptosis Inhibition
by: Shasha Tian, et al.
Published: (2025-01-01)

Appendicitis After Initiation of Tirzepatide
by: Chan G, et al.
Published: (2025-01-01)

The Effects of Oral Semaglutide on Hepatic Fibrosis in Subjects with Type 2 Diabetes in Real-World Clinical Practice: A Post Hoc Analysis of the Sapporo-Oral SEMA Study
by: Hiroya Kitsunai, et al.
Published: (2025-01-01)

Case report: Long-term efficacy and safety of semaglutide in the treatment of syndromic obesity in Prader Willi syndrome - case series and literature review
by: Andrijana Koceva, et al.
Published: (2025-01-01)

Effect of glucagon-like peptide-1 receptor agonists in osteoarthritis: A systematic review of pre-clinical and human studies
by: Jacinta Cheng, et al.
Published: (2025-03-01)

Tirzepatide in Sport: A Comprehensive Review of its Metabolic Impacts and Potential Applications for Athletes
by: Wiktor Biesiada, et al.
Published: (2025-01-01)

The Beneficial Effects of GLP-1 Receptor Agonists Other than Their Anti-Diabetic and Anti-Obesity Properties
by: Chenqi Lu, et al.
Published: (2024-12-01)

Efficacy and safety of glucagon-like peptide-1 receptor agonists in the elderly versus non-elderly patients with type 2 diabetes mellitus: insights from a systematic review
by: Yao Wang, et al.
Published: (2024-06-01)

Is Weight Loss the Main Driver for A1C Improvement by Glucagon‐Like Peptide 1 (GLP‐1) Receptor Agonists? A 2.5‐Year Analysis in Real‐World Clinical Practice
by: Marwa Al‐Badri, et al.
Published: (2025-01-01)

Impact of Hospitalization on Continuation of SGLT2 Inhibitors and GLP-1 Receptor Agonists for Comorbidities in Patients with Type 2 Diabetes
by: Bethany Murphy, et al.
Published: (2025-01-01)

The impact of glucagon-like peptide-1 (GLP-1) agonists in the treatment of eating disorders: a systematic review and meta-analysis
by: Hanieh Radkhah, et al.
Published: (2025-02-01)

Neuropsychiatric adverse events associated with Glucagon-like peptide-1 receptor agonists: a pharmacovigilance analysis of the FDA Adverse Event Reporting System database
by: Wenchao Lu, et al.
Published: (2025-01-01)

One step closer to solving the mystery of the anti‐inflammatory effects of glucagon‐like peptide‐1 receptor agonists
by: Hirotaka Watada
Published: (2025-02-01)

Efficacy and safety of once-weekly semaglutide monotherapy in a young subject with Prader-Willi syndrome, obesity, and type 2 diabetes: a case report
by: Elisa Dinoi, et al.
Published: (2025-02-01)

Glucagon like peptide-1 (GLP-1) agonists and cardiometabolic protection: historical development and future challenges
by: Francisco Westermeier, et al.
Published: (2025-01-01)

GLP-1 Receptor Agonists’ Impact on Fertility - A Review
by: Joanna Wojda, et al.
Published: (2025-02-01)

Unlocking the Potential of Receptor-Based Approaches in Diabetes Treatment
by: Mohsina Patwekar, et al.
Published: (2025-01-01)

Effectiveness and Side Effect Incidence in a Real-World Digital Weight-Loss Service Using Compounded Semaglutide: A Retrospective Comparative Study
by: Louis Talay, et al.
Published: (2024-10-01)

Review: Agonistics. Thinking the World Politically de Chantal Mouffe
by: José Fernández Vega
Published: (2014-01-01)

Chemotherapy in synergy with innate immune agonists enhances T cell priming for checkpoint inhibitor treatment in pancreatic cancer
by: Nan Niu, et al.
Published: (2025-01-01)

Comparative efficacy of incretin drugs on glycemic control, body weight, and blood pressure in adults with overweight or obesity and with/without type 2 diabetes: a systematic review and network meta-analysis
by: Song Liu, et al.
Published: (2025-02-01)

Meta-analysis of the clinical efficacy of liraglutide in treating type 2 diabetes mellitus complicated with non-alcoholic fatty liver disease
by: Yuan-Yuan Xu, et al.
Published: (2024-09-01)

Enhanced renoprotective effects of combined glucagon‐like peptide‐1 receptor agonists and sodium‐glucose cotransporter 2 inhibitors in type 2 diabetes mellitus: Real‐world evidence
by: Jian‐Yu Jhu, et al.
Published: (2025-02-01)

Impact of Thrombopoietin Receptor Agonists on Pathophysiology of Pediatric Immune Thrombocytopenia
by: Paschalis Evangelidis, et al.
Published: (2025-01-01)

A Purely Biomanufactured System for Delivering Nanoparticles and STING Agonists
by: Yu‐an Li, et al.
Published: (2025-01-01)

Discovery of a non‐nucleotide stimulator of interferon genes (STING) agonist with systemic antitumor effect
by: Xiyuan Wang, et al.
Published: (2025-01-01)

Research progress of GLP-1RAs in the treatment of type 2 diabetes mellitus
by: Xu He, et al.
Published: (2025-01-01)

Effects of Semaglutide Treatment on Psoriatic Lesions in Obese Patients with Type 2 Diabetes Mellitus: An Open-Label, Randomized Clinical Trial
by: Jelena Petković-Dabić, et al.
Published: (2025-01-01)

Comparative efficacy and safety of GLP-1 receptor agonists for weight reduction: A model-based meta-analysis of placebo-controlled trials
by: Haoyang Guo, et al.
Published: (2025-03-01)

Profile of STING agonist and inhibitor research: a bibliometric analysis
by: Xuemei Wang, et al.
Published: (2025-02-01)

AiGPro: a multi-tasks model for profiling of GPCRs for agonist and antagonist
by: Rahul Brahma, et al.
Published: (2025-01-01)

Unlocking the multifaceted roles of GLP-1: Physiological functions and therapeutic potential
by: Tohada M. AL-Noshokaty, et al.
Published: (2025-06-01)

Narcolepsy treatment: from exorcism and bloodletting to modern therapy with histamine receptor inverse agonists
by: E. Sakalauskaitė-Juodeikienė, et al.
Published: (2020-09-01)

The Application of Incretin-Based Pharmacotherapy in the Contemporary Management of Type 2 Diabetes: A Review of the Literature
by: Jakub Waszczyński, et al.
Published: (2025-01-01)

Semaglutide, type 2 diabetes, and the risk of nonarteritic anterior ischemic optic neuropathy
by: Fernando K. Malerbi, et al.
Published: (2025-01-01)

Reduction of Hepatic Fat Content by Dulaglutide for the Treatment of Diabetes Mellitus: A Two‐Centre Open, Single‐Arm Trial
by: Chuanfeng Liu, et al.
Published: (2025-01-01)